Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol

Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol

Brief description of study

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EO-nonAD) participants,and (3) cognitively normal (CN) control participants. At this time the study is only enrolling participants with cognitive impairments. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease,Mild Cognitive Impairment
  • Age: Between 40 Years - 64 Years
  • Gender: All


Updated on 22 Aug 2023. Study ID: 829602

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center